/////////// Investor Conference Call Q1 2022 Results May 10th, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates gi ...

/////////// Investor Conference Call FY/Q4 2021 Results March 1, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates ...

1 /// JP Morgan Healthcare Conference /// January 10-13, 2022 40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 /////////// Stefan Oelrich Member of the Board of Management of Bayer AG President of the Pharmaceuticals Division Cautionary statements regarding forward-looking information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to mate ...

/////////// Investor Conference Call Q3 2021 Results November 9, 2021 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates ...

| --- | --- | |------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Half-Year | | | Financial Report 2021 | Bayer: Strong growth, guidance upgrade | | | // Group sales at €10.9 billion (Fx & p adj. +12.9%) -- double-digit percentage growth | | | (Fx & p adj.) at all divisions // EBITDA before special items at €2.6 billion (--10.6%), burdened by currency effects ...

/////////// Investor Conference Call Q1 2021 Results May 12, 2021 Werner Baumann, CEO Wolfgang Nickl, CFO RESTRICTED Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the est ...